Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: Impact of combination assays of immune function and CYP3A5 genotype

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 18, Issue 2, 2011, Pages 226-234

  Mizuno, Shugo ^a   Hamada, Takashi ^a   Nakatani, Kaname ^a   Kishiwada, Masashi ^a   Usui, Masanobu ^a   Sakurai, Hiroyuki ^a   Tabata, Masami ^a   Sakamoto, Yuko ^a   Nishioka, Junji ^a   Muraki, Yuichi ^a   Okuda, Masahiro ^a   Nobori, Tsutomu ^a   Isaji, Shuji ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcineurin inhibitor; Cytochrome P450 3A genotype; Immune functional assay; Living donor liver transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGED; ALLELE; ARTICLE; ASSAY; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; GENOTYPE; HUMAN; IMMUNE RESPONSE; INFECTIOUS COMPLICATION; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MALE; PATIENT CODING; PATIENT MONITORING; PERIPHERAL LYMPHOCYTE;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANTIGENS, CD4; CYTOCHROME P-450 CYP3A; DNA; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; IMMUNITY, CELLULAR; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79959856088     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-010-0335-8     Document Type: Article

References (19)

1. Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, Shimada T, Funae Y. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol. 1994; 47:727-35. (Pubitemid 24094278)
2. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-54.
3. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, Wojnowski L. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 2005;51: 1374-81. (Pubitemid 41060869)
4. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34: 836-47.
5. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc. 2005;37:1730-2.
6. Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation. 2005;80:977-84. (Pubitemid 41552896)
7. Buttgereit F, Burmester GR, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today. 2000;21:192-9. (Pubitemid 30184792)
8. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-8. (Pubitemid 44395237)
9. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003;17:77-88. (Pubitemid 36833776)
10. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics. 2002;12:331-4. (Pubitemid 34620661)
11. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem. 2001;34(1):9-16. (Pubitemid 32178500)
12. Zeevi A, Britz JA, Bentlejewski CA, Guaspari D, Tong W, Bond G, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol. 2005;15: 17-24. (Pubitemid 41435099)
13. Mendler M, Kwok H, Franco E, Baron P, Weissman J, Ojogho O, et al. Monitoring peripheral blood CD4+ adenosine triphosphate activity in a liver transplant cohort: insight into the interplay between hepatitis C virus infection and cellular immunity. Liver Transpl. 2008;14(9):1313-22.
14. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2009;15(12):1834-42.
15. Cabrera R, Ararat M, Soldevila-Pico C, Dixon L, Pan JJ, Firpi R, et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl. 2009;15(2):216-22.
16. Tahara H, Tanaka Y, Ishiyama K, Ide K, Shishida M, Irei T, et al. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Transpl Int. 2009;22(8): 805-13.
17. Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation. 2009;87(8):1225-31.
18. Hosohata K, Masuda S, Yonezawa A, Sugimoto M, Takada Y, Kaido T, et al. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study. Drug Metab Pharmacokinet. 2009;24(5):458-63.
19. Usui M, Isaji S, Kobayashi M, Osawa I, Iida T, Sakurai H, et al. Selection of calcineurin inhibitar after living-donor liver transplantation based on CYP3A5 gene polymorphism: attempt of tailor-made treatment introduction. Am J Transplant. 2007; 7[Suppl 2]:1562.